Recombinant FSH versus human menopausal gonadotropins for ovarian stimulation in IVF cycles: Analysis of outcomes

Year 2002, Volume: 33 Issue: 2, 16 - 19, 01.03.2002

Kenan Sofuoğlu M. Nuri Delikara Selçuk Özden Gazi Yıldırım Toygun Başaran Mehmet Güçlü

Abstract

Objective: To analyze the results of using rFSH and hMG for ovarian stimulation in in vitro fertilization cycles. Material and method: A retrospective analysis of all the treatment cycles between April 2001 and May 2002 were performed. Treatment with hMG was used for 72 patients, whereas 100 patients were treated with rFSH. Results: Of the cycles with embryo transfer, the pregnancy rates were 27.3 % and 20.2 % in the hMGand the rFSH groups, respectively. This difference is not statistically significant (p=0.35). No significant differences were found with regard to the number of mature oocytes, the duration of stimulation, the total amount of gonadotropin used and the fertilization rates. Conclusion: It's found that there was no significant difference between two stimulation regiments in terms of the clinical pregnancy rate.

Keywords

Fertilization in Vitro, Retrospective Studies, Follicle Stimulating Hormone, Menotropins, Ovulation Induction

IVF-ET sikluslarında ovaryen stimulasyon için rekombinant folikül stimulan hormon ve human menopozal gonadotropin kullanımının sonuçlar üzerine etkisi

Abstract

Amaç: Ovulasyon indüksiyonu yapılan IVF-ET olgularında rekombinant folikul stimulant hormon (rFSH) ve human menopozal gonadotropin (hMG) kullanımının in-vitro fertilizasyon sonuçları üzerine etkisinin araştırılması. Materyal ve Metod: Nisan 2001-Mayıs 2002 tarihleri arasında Tüp Bebek Ünitesinde ovulasyon indüksiyonu yapılan kadınların dosyalarının retrospektif olarak incelenmesi ile hMG kullanılan 72 ve rFSH kullanılan 100 olgu analiz edilmiştir. Bulgular: Embryo transferi yapılan sikluslarda, gebelik oranlan hMG grubunda % 27.3 ve rFSH grubunda % 20.2 olarak saptanmıştır. Bu fark istatistik! olarak anlamlı değildir( p=0.35) hMG ve rFSH arasında elde edilen matür oosit, indüksiyon süresi, kullanılan total gonadotropin dozu ve fertilizasyon oranları ile ilişkili olarak hiçbir istatistiki anlamlı fark bulunmamıştır. Sonuç: Klinik gebelik oranları açısından her iki stimulasyon rejimi arasında anlamlı fark bulunmadığı saptandı.

Keywords

İnvitro fertilizasyon, Geriyedönük çalışma, Folikül uyarıcı hormon, Menotropinler, Ovülasyon uyarılması

References

• 1. Agrawal R., Holmes J., Jacobs HS. Follicle stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta analysis. Fertil Steril 2OO0: 73; 338-343
• 2. Daya S, Gunby J., Highes EG. et al. Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotropin in in vitro fertilization outcome. Hum Reprod., 1995: 10;1392-1396 3. Levy D.P., Navarro J.M., Schattman G.L., Davis OJC Rosenwaks Z. The role of LH in ovarian stimulation. Exogenous LH: lets design the future. Hum Reprod. 2000:11; 2258-2265. 4. Giudice F., Crisci C.,Eshkol A. et al. Composition of commercial gonadotropin preparations extracted from human post menopausal urine: characterization of non-gonadotropin proteins. Hum Reprod. l994:9;2291-2299 5. Schats R., Sutter PD., Bassil S., Kremer J.A.M.,set al. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. Hum reprod
• 2000;15:1691-1697
• 6. Check J.H. HMG is possibly superior to recombinant FSH for IVF. Hum Reprod
• 2001;16:2473-2477 7. Ng EHY, Lau EYL., Yeung WSB and Ho PC. HMG is as good as human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Hum Reprod 2001:16; 319-325 8. Imthurn B., Macas E., Rosselli M. et al. Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotropin. Hum Reprod.l996:ll;2387-2391 9. Jacob S., Drudy L., Conroy R.et al. Outcome from consecutive in vitro fertilization/intracytoplasmic sperm injection attemps in the final group treated with urinary gonadotropins and the first group treated with recombinant follicle stimulating hormone. Hum Reprod. 1998: 13; 1783-1787 10. Strehler E, Abt M., El Danasoouri I. et al. Impact of recombinant follicle stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome. Fertil Steril 2001: 75; 332-336